guest ::
| Home > Publications database > Statin-based endothelial prophylaxis and outcome after allogeneic stem cell transplantation. > print |
| Home > Publications database > Statin-based endothelial prophylaxis and outcome after allogeneic stem cell transplantation. > print |
| 001 | 182099 | ||
| 005 | 20240229145708.0 | ||
| 024 | 7 | _ | |a 10.1111/eci.13883 |2 doi |
| 024 | 7 | _ | |a pmid:36199203 |2 pmid |
| 024 | 7 | _ | |a 0014-2972 |2 ISSN |
| 024 | 7 | _ | |a 0960-135X |2 ISSN |
| 024 | 7 | _ | |a 1365-2362 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2022-02417 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Pabst, Caroline |b 0 |
| 245 | _ | _ | |a Statin-based endothelial prophylaxis and outcome after allogeneic stem cell transplantation. |
| 260 | _ | _ | |a Oxford [u.a.] |c 2023 |b Wiley-Blackwell |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1674743156_19106 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2023 Feb;53(2):e13883 |
| 520 | _ | _ | |a Allogeneic haematopoietic stem cell transplantation (alloSCT) often remains the only curative therapy for hematologic malignancies. Although the management of transplant-associated adverse events considerably improved over the last decades, nonrelapse mortality (NRM) remains a challenge, and endothelial dysfunction was identified as a major contributor to NRM.Statin-based endothelial prophylaxis (SEP) has been implemented in the standard of care in our transplant centre to reduce NRM caused by endothelial injury. Here, we retrospectively analysed the impact of SEP on clinical outcome in a cohort of 347 alloSCT patients.SEP (n = 209) was associated with significantly reduced NRM (hazard ratio 0.61, 95% CI 0.38-0.96) and better overall survival (OS) after acute graft-versus-host disease (HR 0.59, 95% CI 0.37-0.93). Subgroup analyses showed that the NRM benefit was mainly found in patients with an intermediate endothelial activation and stress index (EASIX), while relapse risk was not affected. On day 100 post-alloSCT, patients receiving SEP had significantly higher levels of the rate-limiting enzyme of tryptophan metabolism, indoleamine 2,3-dioxygenase (IDO), higher kynurenine to tryptophan ratios as a proxy of IDO activity and tended to have lower levels of the endothelial injury marker ST2 (p = .055). No significant differences in interferon-gamma or IL18 levels were observed. These biomarker signatures suggest that the beneficial effects of SEP might be mediated by both endothelial protection and immunomodulation.Together, these data suggest that SEP improves NRM and OS post-alloSCT in particular in patients with intermediate endothelial risk and provide first mechanistic clues about its potential mode of action. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 542 | _ | _ | |i 2022-10-11 |2 Crossref |u http://creativecommons.org/licenses/by/4.0/ |
| 542 | _ | _ | |i 2022-10-11 |2 Crossref |u http://doi.wiley.com/10.1002/tdm_license_1.1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a allogeneic stem cell transplantation |2 Other |
| 650 | _ | 7 | |a endothelial damage |2 Other |
| 650 | _ | 7 | |a endothelial protection |2 Other |
| 650 | _ | 7 | |a immunosuppression |2 Other |
| 650 | _ | 7 | |a statin |2 Other |
| 650 | _ | 7 | |a thrombotic microangiopathy |2 Other |
| 700 | 1 | _ | |a Schreck, Nicholas |0 P:(DE-He78)0d054b6843ace36d1c965b6cb938d1c9 |b 1 |u dkfz |
| 700 | 1 | _ | |a Benner, Axel |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 2 |u dkfz |
| 700 | 1 | _ | |a Hegenbart, Ute |b 3 |
| 700 | 1 | _ | |a Schönland, Stefan |b 4 |
| 700 | 1 | _ | |a Radujkovic, Aleksandar |b 5 |
| 700 | 1 | _ | |a Schmitt, Michael |b 6 |
| 700 | 1 | _ | |a Müller-Tidow, Carsten |b 7 |
| 700 | 1 | _ | |a Orsatti, Laura |b 8 |
| 700 | 1 | _ | |a Dreger, Peter |b 9 |
| 700 | 1 | _ | |a Luft, Thomas |b 10 |
| 773 | 1 | 8 | |a 10.1111/eci.13883 |b Wiley |d 2022-10-11 |n 2 |3 journal-article |2 Crossref |t European Journal of Clinical Investigation |v 53 |y 2022 |x 0014-2972 |
| 773 | _ | _ | |a 10.1111/eci.13883 |0 PERI:(DE-600)2004971-7 |n 2 |p e13883 |t European journal of clinical investigation |v 53 |y 2022 |x 0014-2972 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:182099 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)0d054b6843ace36d1c965b6cb938d1c9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-19 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J CLIN INVEST : 2022 |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-19 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-19 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J CLIN INVEST : 2022 |d 2023-08-19 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |a 10.1182/blood-2011-02-334821 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1038/s41409-021-01390-y |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1007/s00277-022-04820-z |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.jtct.2022.08.003 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.3389/fimmu.2021.695037 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1182/blood.V104.11.1235.1235 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1097/MOH.0000000000000687 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1056/NEJMc1700185 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1038/bmt.2017.119 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1038/s41409-019-0703-1 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.3324/haematol.2019.238790 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/S2352-3026(17)30108-4 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1038/s41408-019-0247-z |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1186/s12885-020-07317-y |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1182/blood-2020-139615 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.3389/fimmu.2021.634416 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.amjcard.2005.06.009 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.molmed.2007.11.004 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.jaci.2010.08.005 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.3892/mmr.2018.8537 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1038/s41380-019-0401-9 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |1 Mohammadi M |y 2016 |2 Crossref |o Mohammadi M 2016 |
| 999 | C | 5 | |a 10.1200/JCO.2013.50.8747 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.bbmt.2010.05.006 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.bbmt.2015.07.034 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.bbmt.2013.10.014 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1002/(sici)1096-8652(200005)64:1<32::aid-ajh6>3.0.co;2-n |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1097/00007890-197410000-00001 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.3324/haematol.10699 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.bbmt.2005.06.001 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.xcrm.2021.100409 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1111/j.1365-2362.2009.02234.x |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1016/j.ebiom.2019.10.024 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1007/s10456-020-09730-0 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1097/TP.0000000000003108 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1182/bloodadvances.2020003418 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1182/blood-2007-08-106005 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.3324/haematol.2020.253716 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1038/bmt.2017.121 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.3389/fimmu.2019.02339 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.2215/CJN.02070508 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1093/ndt/gfh385 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1378/chest.14-3138 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1158/0008-5472.CAN-12-0569 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.4049/jimmunol.1001628 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1038/sj.cdd.4401073 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.3389/fimmu.2019.02565 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1038/s41416-019-0664-6 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1007/s00277-019-03682-2 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1007/s11010-009-0244-9 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.3390/ijms21249385 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1056/NEJMoa1213299 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1002/cncr.24531 |9 -- missing cx lookup -- |2 Crossref |
| 999 | C | 5 | |a 10.1038/ni.2088 |9 -- missing cx lookup -- |2 Crossref |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|